[

gamaleya institute

]
Gamaleya’s Alexander Gintsburg said on Sunday that the new Russian drug would be made up of “monoclonal antibodies.”(Reuters)

Russia to test new Covid-19 antibody drug from new year

By Reuters | Posted by Srivatsan K C | Moscow
PUBLISHED ON DEC 28, 2020 07:43 PM IST
Alexander Gintsburg, director of the Gamaleya Institute, was cited by the RIA news agency as saying that he hoped trials for the new antibody-based drug would begin in the autumn of 2021.
Close
The Gamaleya Institute, which developed and is manufacturing the vaccine, is gradually joining forces with private Russian pharmaceutical firms, which are gearing up to mass produce the shot at their plants.(Reuters file photo)
The Gamaleya Institute, which developed and is manufacturing the vaccine, is gradually joining forces with private Russian pharmaceutical firms, which are gearing up to mass produce the shot at their plants.(Reuters file photo)

Russia’s Covid-19 vaccine trial slows as demand for doses soar amid shortage

By Reuters | Posted by Deepali Sharma | Moscow
UPDATED ON OCT 30, 2020 07:24 AM IST
Eight of the 25 clinics in capital Moscow said the vaccination of new participants was temporarily on hold. Staff at three clinics, meanwhile, said they had run out specifically of the first component of the two-dose jab. The second component is injected 21 days after the first.
Close
SHARE
Story Saved